In April 2022, HOPA submitted a proposal to the Board of Pharmacy Specialties to continue to provide professional development programs for the recertification of board-certified pharmacists. With BPS's approval, HOPA is proud to provide Board Certified Oncology Pharmacy (BCOP) continuing education for another seven years. The new contract begins January 1, 2024 and runs through December 31, 2030.

Read the announcement: BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024

HOPA Provides at Least 60 BCOP CEs Each Year

Each year, HOPA provides at least 60 BCOP Continuing Education Credits for members and other board certified hematology/oncology pharmacists. Explore the latest BCOP Updates and BCOP Self-Study Releases and more!

Tools and Resources Late Breaking News

Related Articles

Read all latest news Right Pointing Arrow
acute leukemia image
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Revumenib

March 07, 2025

Andres Mariano, PharmD, PGY-2 Pediatric Oncology Pharmacy Resident, and Stephen Eng, PharmD, BCOP, Clinical Pharmacist - both from Memorial Sloan Kettering Cancer Center, New York, NY - write about revumenib (Revuforj).

Cancer cell image
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Datopotamab deruxtecan-dlnk

March 07, 2025

Kasey Jackson, PharmD, BCOP, Clinical Oncology Pharmacy Specialist at Medical University of South Carolina, Charleston, SC, writes about datopotamab deruxtecan-dlnk (Datroway).

Squamous cell carcinoma
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Cosibelimab-ipdl

March 03, 2025

Nathan Schieldt, PharmD, PGY2 Oncology Resident; William Morrissey, PharmD, PGY2 Oncology Resident; and Anna Clennon, PharmD, BCOP Clinical Pharmacist - all from Aurora St. Luke's Medical Center, Milwaukee, WI - write about cosibelimab-ipdl.